The primary cilium, a solitary, antenna-like projection found on nearly every mammalian cell, has emerged as a crucial sensory organelle responsible for detecting extracellular mechanical and chemical signals. In the context of bone biology, the functionality of primary cilia has remained enigmatic, particularly in preosteoclasts, the precursor cells to osteoclasts responsible for bone resorption. This new study presents compelling evidence that exercise triggers mechanosensitive responses in these cells via their primary cilia, promoting a local microenvironment conducive to periosteal bone accretion.

Delving deeper into the molecular cascade, the researchers demonstrated that mechanical loading from exercise stimulates the elongation and activation of primary cilia on preosteoclasts. This morphological transformation enhances the cells’ ability to sense biomechanical cues, triggering intracellular signaling pathways that modulate gene expression relevant to bone remodeling. Notably, the activation of these cilia leads to the secretion of osteogenic factors that directly facilitate periosteal bone formation, suggesting an autocrine and paracrine communication network within the bone niche.

This study employed advanced imaging techniques, including high-resolution confocal microscopy and live-cell imaging, to visualize primary cilium dynamics in response to mechanical stimuli. The dynamically elongated cilia serve as mechanotransducers, converting biomechanical inputs into biochemical signals that engage downstream effectors, including calcium influx channels and Hedgehog signaling pathways. Such mechanotransduction underscores the intimate relationship between physical activity and bone homeostasis, providing a refined understanding of how mechanical forces optimize skeletal strength and integrity.

The researchers further conducted loss-of-function experiments by genetically ablating or impairing primary cilium formation specifically in preosteoclasts, revealing a significant attenuation of exercise-induced periosteal bone growth. These findings unequivocally establish primary cilia as indispensable mediators in the mechanical regulation of bone formation, specifically within the periosteal compartment, which is critical for cortical bone thickening and overall skeletal robustness.

Moreover, the study investigated the downstream effectors of cilia-mediated signaling, identifying key molecular players, such as the polycystin complex and specific transcription factors that modulate osteogenic gene expression. Exercise-induced activation of these pathways in preosteoclasts appears to foster a favorable balance between bone resorption and formation, tilting the scale towards anabolic processes that reinforce the periosteum — the outer fibrous layer essential for bone strength and repair.

This novel insight into preosteoclast function challenges previous dogma that primarily linked osteoblasts and osteocytes as the main responders to mechanical stimuli in bone remodeling. The role of preosteoclasts, traditionally seen as precursors to bone-resorbing osteoclasts, is now redefined as active regulators of periosteal bone formation through ciliary mechanosensing. Such a paradigm shift opens new avenues for targeting preosteoclast cilia to potentiate skeletal resilience, especially in aged or osteoporotic populations where bone fragility is a major concern.

Importantly, the researchers correlated their cellular and molecular findings with in vivo models of exercise, confirming that mechanical loading through controlled physical activity robustly enhances periosteal bone accrual dependent on intact primary cilia function. These in vivo validations accentuate the translational potential of manipulating cilia-mediated mechanotransduction pathways as a therapeutic strategy to mimic the beneficial effects of exercise in bone tissue.

In terms of clinical applications, the elucidation of exercise-stimulated primary cilia function on preosteoclasts heralds promising implications for developing targeted pharmacological agents that can activate or sensitize these mechanosensors. Such agents could potentially serve as adjunctive therapies for patients unable to perform adequate physical activity due to injury, illness, or aging, thereby preserving or enhancing bone mass and reducing fracture risk.

The intersection of mechanobiology and skeletal physiology, as highlighted by this study, reflects a broader trend in biomedical research emphasizing the importance of physical forces in cellular function and tissue regeneration. Understanding how diverse bone cell populations transcend their classical roles to integrate mechanical cues enriches our knowledge of skeletal biology and may revolutionize treatment paradigms for musculoskeletal disorders.

Given the complexity of bone remodeling, which requires the coordinated interplay among osteoblasts, osteoclasts, osteocytes, and now preosteoclasts, the identification of primary cilia on preosteoclasts as mechanosensors adds a critical piece to the puzzle. This refined understanding emphasizes the necessity for a holistic approach when designing interventions aimed at improving bone health, considering the intricate cellular crosstalk influenced by mechanical stimuli.

The temporal dynamics of cilia activation and periosteal bone formation revealed by this research also suggest that the timing and intensity of exercise regimens could be optimized to maximize bone anabolic responses. Personalized exercise prescriptions based on mechanotransduction insights might emerge as a future avenue for maximizing skeletal benefits while minimizing injury risk.

Furthermore, this discovery invites an exploration of primary cilia function beyond bone tissue, potentially uncovering similar mechanosensory roles in other mechanically active tissues such as cartilage, muscle, and vascular endothelium. The expanding relevance of cilia-mediated signaling mechanisms underscores a fundamental biological principle linking physical forces to tissue homeostasis across organ systems.

As the field moves forward, integrating multi-omics approaches, mechanobiology, and in vivo imaging will be crucial to unravel the intricate signaling networks governed by primary cilia on various cell types. The therapeutic exploitation of these pathways holds immense promise, particularly in aging populations where maintaining bone strength is imperative for mobility and quality of life.

In conclusion, the revelation that exercise-stimulated primary cilia on preosteoclasts promote periosteal bone formation is a scientific milestone that redefines our understanding of skeletal mechanobiology. This seminal work by Kim JM, Lee YS, Kim MJ, and colleagues not only advances bone biology but also opens innovative prospects for combating bone degenerative diseases through biomechanically informed therapeutic interventions. The marriage of cellular mechanosensing with exercise physiology marks a new frontier in biomedical research, poised to generate impactful health solutions for an aging global population.

Subject of Research: Mechanical regulation of periosteal bone formation through primary cilia on preosteoclasts induced by exercise.

Article Title: Exercise-stimulated primary cilia on preosteoclasts promote periosteal-bone formation.

Article References:
Kim, JM., Lee, YS., Kim, M.J. et al. Exercise-stimulated primary cilia on preosteoclasts promote periosteal-bone formation. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01765-5

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01765-5

Keywords: Primary cilia, preosteoclasts, mechanotransduction, periosteal bone formation, exercise, bone remodeling, skeletal mechanobiology, osteogenic signaling, polycystin complex, Hedgehog pathway, bone health, osteoporosis

Recent advances in functional foods and nutraceuticals have turned scientific attention toward bioactive compounds derived from natural sources. Among these, egg yolk—a complex biological matrix rich in proteins, phospholipids, and lipoproteins—has emerged as a promising candidate for bone health interventions. Phosvitin, a major phosphoprotein in egg yolk, is known for its mineral-binding properties, suggesting a potential regulatory role in bone metabolism. However, mechanistic insights into how specific egg yolk-derived fractions influence the cellular constituents responsible for bone resorption have remained elusive.

A groundbreaking study from the University of Alberta, recently published in Food Science of Animal Products, elucidates the inhibitory effects of water-soluble egg yolk hydrolysates on osteoclastogenesis, the process by which osteoclasts—the bone-resorbing cells—differentiate and mature. The research primarily focuses on distinct fractions obtained from egg yolk hydrolysates, notably three water-soluble fractions designated as FA, FB, and FC, with further subfractionation of FC into FC1 and FC2 based on molecular weight (<3 kDa and >3 kDa, respectively).

This investigation employed RANKL-induced RAW264.7 macrophage cultures, a well-established in vitro model for osteoclast differentiation, to systematically assess the impact of these hydrolysate fractions on osteoclast formation and function. The FC fraction demonstrated superior efficacy in attenuating osteoclastogenesis compared to FA and FB, with the FC1 subfraction exhibiting markedly enhanced inhibitory potency. Quantitative analyses revealed that at a concentration of 1,000 µg/mL, FC1 reduced the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts by more than 50%, underscoring its robust anti-osteoclastogenic capacity.

At a molecular level, FC1 modulates pivotal signaling cascades implicated in osteoclast differentiation. The receptor activator of nuclear factor κB ligand (RANKL) activates mitogen-activated protein kinases (MAPKs)—including p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)—which orchestrate the transcription of osteoclastogenic genes. The study demonstrates that FC1 effectively suppresses the phosphorylation of these MAPK pathway mediators in a dose-dependent manner, disrupting the intracellular signaling necessary for osteoclast maturation.

Beyond inhibition of osteoclastogenesis, FC1 exerts pro-apoptotic effects on mature osteoclasts, a dual mechanism beneficial for curbing excessive bone resorption. Flow cytometric analyses detected increased populations of both early and late apoptotic cells upon FC1 treatment, signifying its ability to induce programmed cell death in osteoclasts. This two-pronged approach—impeding differentiation and inducing apoptosis—positions FC1 as a unique bioactive compound with the potential to recalibrate bone remodeling homeostasis more effectively than agents acting via a single pathway.

The implications of these findings extend beyond basic science, heralding a novel avenue for osteoporosis management via functional foods or dietary supplements enriched in egg yolk-derived bioactive fractions like FC1. By integrating these natural compounds into therapeutic strategies, it may be possible to alleviate patient concerns regarding synthetic drug side effects while sustaining efficacious control of pathological bone loss.

Jianping Wu, the senior researcher spearheading this project at the University of Alberta, highlights the therapeutic promise of FC1. “Our isolation of the water-soluble FC1 fraction from egg yolk uncovers a natural agent capable of simultaneously suppressing osteoclast differentiation and promoting apoptosis. This dual action could revolutionize current approaches to osteoporosis treatment, especially considering the regulatory complexity of bone resorption pathways.”

While the in vitro results are compelling, the researchers emphasize the necessity of advancing to in vivo studies to verify FC1’s efficacy in whole-animal models. Pharmacokinetics, bioavailability, and metabolic stability will be critical parameters in determining the feasibility of FC1’s translation into clinical applications. Future investigations will also need to elucidate the structural identity of the active peptides or molecules within FC1 responsible for the observed biological effects.

Moreover, the sustainable sourcing of egg yolk protein hydrolysates presents an attractive advantage for scalable production, potentially leveraging existing agricultural and food industry infrastructures. This aligns with the broader global trend toward natural product development that is environmentally and economically viable.

Egg yolk hydrolysates like FC1 could also synergize with other bone health-promoting agents, such as calcium, vitamin D, and phytoestrogens, providing multifaceted nutritional strategies to prevent or mitigate osteoporosis. The integration of such bioactive fractions into functional foods or nutraceuticals could offer accessible, non-pharmacological options suitable for widespread consumer use.

In conclusion, this pioneering research unveils water-soluble egg yolk hydrolysate FC1 as a potent inhibitor of osteoclastogenesis and inducer of osteoclast apoptosis, identifying a natural compound with significant potential to transform osteoporosis management. As the aging demographic continues to expand globally, innovative and safe interventions like FC1-derived products may prove instrumental in reducing the burden of osteoporotic fractures and improving the quality of life for millions.

Subject of Research: Natural bioactive compounds from egg yolk hydrolysates inhibiting osteoclastogenesis for osteoporosis management.

Article Title: Water-soluble egg yolk hydrolysate shows osteoclastogenesis inhibitory effects

News Publication Date: 10 June 2025

Web References:

• DOI: 10.26599/FSAP.2025.9240125
• Food Science of Animal Products Journal

Image Credits: Food Science of Animal Products, Tsinghua University Press

Keywords: Osteoporosis, osteoclastogenesis, egg yolk hydrolysate, FC1 fraction, MAPK signaling, apoptosis, bone resorption, natural bioactive compounds, functional foods, bone health

The significance of osteoclasts in maintaining skeletal integrity cannot be overstated. These specialized, multinucleated cells originate from the monocyte/macrophage lineage and are responsible for bone resorption, a process balanced by osteoblast-driven bone formation. Dysregulation in osteoclast activity, often stimulated by RANKL, leads to pathological conditions marked by bone fragility, fragility fractures, and chronic skeletal deformities. The quest for effective agents that can selectively inhibit osteoclast differentiation without adverse effects on bone formation remains a formidable challenge in clinical therapeutics. Against this backdrop, Han and colleagues have embarked on an in-depth investigation to decipher the molecular underpinnings through which Lycii fructus water extracts exert inhibitory effects on RANKL-induced osteoclastogenesis.

Central to their research is zeaxanthin, a xanthophyll carotenoid abundant in goji berries, renowned for its antioxidant and anti-inflammatory properties. By isolating zeaxanthin and assessing its impact on osteoclast precursor cells under RANKL stimulation, the study delivers compelling evidence that this bioactive compound interferes with critical signaling cascades imperative for osteoclast differentiation. More specifically, zeaxanthin appears to attenuate the activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), a master transcription factor that orchestrates the expression of osteoclast-specific genes. The dampening of NF-κB activity thus effectively halts the cellular programs that culminate in mature osteoclast formation.

The researchers employed a series of comprehensive in vitro assays, utilizing macrophage-lineage cell cultures treated with RANKL to simulate osteoclastogenesis. Treatment with Lycii fructus water extracts resulted in a significant decrease in the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells—a hallmark of osteoclast identity—without compromising cell viability. This selective inhibitory profile underscores the therapeutic potential of natural compounds that target pathological differentiation processes while preserving cellular health. Further confirming these findings, quantitative PCR analyses revealed downregulation of key osteoclast-related genes including cathepsin K, matrix metalloproteinase 9 (MMP9), and TRAP, attesting to the molecular suppression of osteoclastogenic pathways.

Intriguingly, the study highlights the dual functionality of Lycii fructus water extracts through their antioxidant effects, which may additionally curtail reactive oxygen species (ROS)-mediated enhancement of osteoclast differentiation. By quenching oxidative stress, zeaxanthin and complementary phytochemicals embedded in the goji berry matrix could inhibit redox-sensitive signaling mechanisms essential for osteoclast maturation. This multifaceted mechanism offers a nuanced approach to bone preservation, integrating both direct transcriptional inhibition and indirect modulation via oxidative stress attenuation.

Beyond cellular assays, the researchers probed signal transduction pathways activated by RANKL, such as MAPK (mitogen-activated protein kinase) and NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1), both indispensable regulators of osteoclast gene expression. Treatment with Lycii fructus extracts led to diminished phosphorylation of ERK, JNK, and p38 MAPKs, culminating in suppressed induction of NFATc1. This cascade interruption effectively stalls the maturation program of osteoclast precursors. Such comprehensive targeting of intracellular signaling nodes emphasizes the robustness of Lycii fructus’s inhibitory action.

The implications of these findings extend beyond basic science and have palpable clinical resonance. Osteoporosis affects millions worldwide, leading to debilitating fractures and elevated healthcare burdens. Current pharmacological interventions, including bisphosphonates and RANKL antibodies (e.g., denosumab), though effective, bear risks of long-term adverse effects such as osteonecrosis and atypical fractures. The advent of natural, dietary-based agents with high safety profiles could revolutionize preventive and adjunctive strategies in bone health management. Lycii fructus, widely consumed for its nutritional benefits, emerges as a promising candidate for functional food development targeting skeletal diseases.

Additionally, this study enriches the growing body of evidence endorsing carotenoids as pivotal modulators of cellular differentiation and inflammation. Zeaxanthin’s capacity to intercept NF-κB and MAPK pathways echoes observations in diverse pathological contexts, underscoring a conserved molecular mechanism that can be harnessed therapeutically. The specificity of zeaxanthin in mitigating osteoclastogenesis without hampering osteoblast function is particularly noteworthy, as it suggests a harmonized effect conducive to bone homeostasis.

Methodologically, the researchers ensured rigorous validation through multiple experimental replicates and controls, underscoring the reproducibility and reliability of their data. The use of water extracts aligns with feasible dietary modalities, enhancing translational potential. While in vivo studies remain requisite for confirming bioavailability, pharmacokinetics, and systemic efficacy, this foundational research lays a compelling groundwork for subsequent clinical exploration.

Furthermore, the interplay between traditional herbal medicine and modern molecular biology is exemplified in this research. Lycii fructus, long utilized in Asian traditional medicine for vision enhancement, immune modulation, and longevity, now gains mechanistic credence in bone pathophysiology. This convergence validates ethnobotanical knowledge and encourages integrative approaches bridging natural compounds with cutting-edge biomedical research.

The study also prompts reflection on the broader role of natural antioxidants in chronic disease modulation. Chronic inflammatory conditions often exacerbate osteoclast activity through heightened cytokine signaling and oxidative stress. By mitigating such pro-osteoclastogenic stimuli, substances like zeaxanthin may exert systemic benefits beyond skeleton-specific effects, offering holistic therapeutic advantages.

Acknowledging the need for nuanced dose optimization and potential synergies with other bioactives, the authors advocate for expanded research encompassing animal models and human clinical trials. Such endeavors are crucial to decipher the comprehensive pharmacodynamics and to establish standardized formulations ensuring consistent therapeutic outcomes.

In summary, Han et al.’s investigation delineates a sophisticated biochemical landscape wherein Lycii fructus water extracts and zeaxanthin impede RANKL-induced osteoclast differentiation via multi-tiered attenuation of signaling pathways and gene expression. These findings enhance understanding of bone biology and introduce promising nutraceutical candidates to combat osteoporosis and related diseases. With the global aging population, such innovations resonate profoundly, heralding a future where dietary interventions complement pharmacotherapy in safeguarding skeletal health.

As the scientific community continues to unravel nature’s pharmacopoeia, this study stands as a testament to the untapped potential residing within traditional botanicals. With further validation and clinical translation, compounds like zeaxanthin might become integral components of personalized medicine paradigms designed to maintain bone integrity, prevent fractures, and improve quality of life worldwide.

Subject of Research: Inhibitory effects of Lycii fructus water extracts and zeaxanthin on RANKL-induced osteoclast differentiation

Article Title: Inhibitory effects of Lycii fructus water extracts and its active ingredient, zeaxanthin, on receptor activator of nuclear factor κB ligand-induced osteoclast differentiation

Article References:
Han, SY., Choi, H., Jo, EH. et al. Inhibitory effects of Lycii fructus water extracts and its active ingredient, zeaxanthin, on receptor activator of nuclear factor κB ligand-induced osteoclast differentiation. Food Sci Biotechnol (2025). https://doi.org/10.1007/s10068-025-01944-6

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10068-025-01944-6

One critical signaling axis that controls the formation and function of osteoclasts is the receptor activator of nuclear factor kappa B ligand (RANKL) and its receptor RANK, which interacts with the intracellular adaptor molecule tumor necrosis factor receptor-associated factor 6 (TRAF6). Upon RANKL’s binding to RANK on osteoclast precursors, TRAF6 is recruited and signals downstream cascades necessary for osteoclast differentiation and activation. This RANK-RANKL-TRAF6 pathway plays a pivotal role in osteoclast biology, making it a prime target for drug development aimed at bone-destructive diseases.

However, the broad physiological roles of the RANKL-RANK-TRAF6 signaling axis impose substantial limitations on therapies that seek to inhibit this pathway globally. Beyond bone metabolism, this signaling network influences immune system function, mammary gland development, and other vital biological processes. Consequently, therapeutics that non-selectively block RANKL-RANK-TRAF6 interactions risk provoking severe off-target effects, including impaired immunity and developmental abnormalities. Additionally, attempts to develop synthetic peptides that disrupt the RANK-TRAF6 interface have historically struggled with poor efficacy, often requiring supraphysiological dosages to exert any meaningful inhibition, thereby compromising their clinical potential.

A groundbreaking study led by Professor Kiyotaka Nishikawa at Doshisha University, Japan, offers a novel paradigm in osteoclast-targeted therapy. Published in Communications Biology, this research introduces a tetravalent peptide named WHD-tet, engineered to modulate the RANK-TRAF6 interaction with unprecedented specificity. Unlike prior peptides, WHD-tet binds TRAF6 multivalently, enabling a high-affinity yet nuanced regulation of downstream signal transduction. More importantly, the researchers developed a cell-permeable derivative, CR4-WHD-tet, which demonstrated potent suppression of osteoclastogenesis in vitro at significantly lower concentrations than any previously reported molecules targeting this pathway.

The mechanism of CR4-WHD-tet’s action is particularly noteworthy. Instead of completely abrogating TRAF6 signaling, the peptide selectively inhibits the recruitment of MKK3, a kinase vital for downstream activation of p38 mitogen-activated protein kinase (p38-MAPK). This subtle modulation effectively prevents the activation of p38-MAPK, a key signaling molecule implicated in terminal osteoclast differentiation and function. By fine-tuning post-receptor signaling events rather than indiscriminately blocking them, CR4-WHD-tet offers a precision approach to osteoclast inhibition, potentially minimizing adverse effects linked to broad-spectrum pathway blockade.

In vivo experiments further validate the therapeutic promise of CR4-WHD-tet. Using mouse models of RANKL-induced bone loss, systemic administration of the peptide significantly attenuated bone resorption, preserving bone density and structural integrity. The peptide’s preferential accumulation in bone tissue is attributed to its high acidic amino acid content, facilitating targeted delivery where osteoclast activity is pathologically elevated. This targeted localization may enhance drug efficacy and reduce systemic toxicity—a major advantage over existing treatments.

Additionally, CR4-WHD-tet’s selective action spares osteoblasts, the bone-forming cells crucial for maintaining skeletal homeostasis. This finding is critical because many anti-osteoclastic agents disrupt the delicate balance between bone resorption and formation, often leading to compromised bone regeneration. By preserving osteoblast viability and functionality, CR4-WHD-tet could foster a more balanced therapeutic outcome, combining inhibition of bone destruction with intact bone formation processes.

Beyond translational implications, this study also illuminates the temporal complexity inherent to osteoclast differentiation signaling pathways. It underscores MKK3’s pivotal function at specific stages of osteoclastogenesis—particularly in controlling the nuclear translocation of p38-MAPK during late differentiation phases. This insight refines current understanding of osteoclast biology, revealing stage-specific molecular targets that can be exploited to design more effective and tailored therapies.

The significance of these findings extends beyond bone disease treatment. The concept of fine-tuning intracellular signaling cascades rather than bluntly inhibiting them heralds a shift in drug design philosophy, emphasizing modulation over suppression. Such an approach may be broadly applicable to other signaling pathways involved in diverse diseases, enabling the development of agents with higher efficacy and fewer side effects.

Professor Nishikawa articulates this perspective, noting that the tetravalent peptide’s selective inhibition mechanism “represents a novel type of therapeutic agent for osteoclast-related diseases that could circumvent the side effects associated with conventional medications.” This pioneering strategy addresses the long-standing challenge of dissecting complex signaling networks to achieve targeted intervention, marking a significant stride in molecular medicine.

As osteoporotic fractures and arthritis-related bone damage continue to impose a heavy burden on healthcare systems worldwide, innovative therapies like CR4-WHD-tet could revolutionize patient management. By safeguarding bone density and minimizing systemic adverse effects, such treatments hold the prospect of dramatically improving patient outcomes and quality of life.

Looking ahead, further preclinical and clinical studies are warranted to assess the safety, efficacy, and pharmacokinetics of CR4-WHD-tet in human populations. Optimization of peptide delivery methods and investigations into long-term effects will be critical to translating this promising molecule into a clinically viable option. Nevertheless, this research lays a robust foundation for next-generation therapeutics that precisely calibrate intracellular signaling to combat bone-destructive diseases.

In summation, the work led by Professor Nishikawa and colleagues redefines the therapeutic landscape for osteoclast-related disorders. By leveraging a tetravalent peptide to precisely modulate RANK-TRAF6-dependent signaling, they demonstrate a novel, effective, and potentially safer approach to controlling pathological bone resorption. This advancement not only enriches scientific understanding of osteoclast biology but also ignites hope for millions suffering from debilitating bone diseases, bringing the vision of fine-tuned molecular therapy closer to reality.

Subject of Research: Animals

Article Title: Clustered peptide regulating the multivalent interaction between RANK and TRAF6 inhibits osteoclastogenesis by fine-tuning signals

News Publication Date: 22-Apr-2025

Web References: http://dx.doi.org/10.1038/s42003-025-08047-2

Image Credits: Professor Kiyotaka Nishikawa from Doshisha University, Japan

Keywords: Health and medicine, Bone diseases